Guardant Health AMEA is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Chance of snow 80%. Industry analysts compare market participants and measure performance through in-depth interviews, analyses, and extensive secondary research to identify best practices in the industry. Visit us online at www.guardanthealthamea.com. Guardant Health, Inc. Condensed Consolidated Balance Sheets (unaudited) (in thousands, except share and per share data) September 30, 2020 December 31, 2019 ASSETS The MarketWatch News Department was not involved in the creation of this content. Guardant Health News: This is the News-site for the company Guardant Health on Markets Insider. Prakash Rajapress@guardantamea.com www.guardanthealthamea.com. Guardant Health, Inc. (Nasdaq: GH) today announced it will report financial results for the third quarter 2020 after market close on Thursday, November 5, 2020. Guardant Health, Inc. (Nasdaq: GH) today announced its intention to offer, subject to market and other conditions, $1,000,000,000 aggregate principal amount of convertible senior notes due 2027 (the "notes") in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). Attaining loyal customers that become brand advocates allows the company to grow and achieve a market leadership position. Yes! Guardant Health, Inc. (Nasdaq: GH) today announced it will report financial results for the third quarter 2020 after market close on Thursday, Novembe Guardant Health … node.dataset.value : node.getAttribute('data-value'); if (selectedValue) { for (var j = 0; j < node.options.length; j++) { if(node.options[j].value === selectedValue) { node.options[j].selected = 'selected';break;}}}}}, Do Not Sell My Personal Information (CA Residents Only). Get up-to-the-minute news sent straight to your device. Low 22F. Find the latest news headlines from Guardant Health, Inc. Common Stock (GH) at Nasdaq.com. Success! (1) Net Loss attributable to Guardant Health, Inc. common stockholders is the most directly comparable GAAP operating financial measure. A high-level overview of Guardant Health, Inc. (GH) stock. Oct. 16, 2020- Guardant Health, Inc. (Nasdaq: GH) today announced it will report financial results for the third quarter 2020 after market close on Thursday, November 5, 2020 . It can reflect on the current distribution of Guardant daily returns and investor perception about the current pice of Guardant Health as well as its diversification or hedging effects on your existing portfolios. ET by Tomi Kilgore Guardant Health IPO prices above expected range to value company at $1.6 billion Today, Guardant makes most of its money selling its Guardant360 test, which measures 74 cancer-related genes in ctDNA. Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, has … This accolade is a testament to the success of the company's flagship liquid biopsy, the Guardant360® test, which oncologists are using to guide treatment decisions for advanced stage cancer patients. Volume today is 704,441 compared to average volume of 840,411. nodes[i].dataset.subscription : nodes[i].getAttribute('data-subscription'); if(status ==='true') {nodes[i].checked = true;}}};var nodes = document.querySelectorAll('#form1783 select[data-value]'); if (nodes) { for (var i = 0; i < nodes.length; i++) { var node = nodes[i]; var selectedValue = node.dataset ? Partly cloudy this evening with more clouds for overnight. You'll now be able to see real-time price and activity for your symbols on the My Quotes of Nasdaq.com. The stock has traded between $102.22 and $104.30 so far today. Enter up to 25 symbols separated by spaces. Winds NE at 5 to 10 mph.. Follow a manual added link. NEW YORK – Guardant Health said today that it has priced an underwritten public offering of 11.5 million shares of its common stock at a $84 per share. Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, today reported financial results for the quarter ended September 30, 2020. Since then, GH stock has increased by 100.1% and is now trading at $125.99. The award recognizes a high degree of innovation with products and technologies and the resulting leadership in terms of customer value and market penetration. Low 22F. Oncologists use this information to … MUMBAI, India, Dec. 14, 2020 /PRNewswire/ -- Guardant Health Asia, Middle East and Africa (AMEA) has won Frost & Sullivan's 2020 Market Leadership Award for Liquid Biopsy in … Snow accumulating 3 to 5 inches. Available in 41 countries across AMEA, the company's Guardant360 test provides quick and accurate comprehensive genomic profiling (CGP) information from a simple blood draw in seven days upon sample receipt in the laboratory. High near 30F. Essentially, the Guardant360 test provides oncologists with CGP information that allows oncologists to see the most current profile of their patient's cancer, prescribe appropriate precision medicine, and recommend targeted treatment," said Supriya Lala, Best Practices Analyst from Frost & Sullivan. Shares of Guardant Health (NASDAQ:GH) fell as much as 10.9% today after the company reported fourth-quarter and full-year 2019 operating results. Guardant Health stock news, alerts, and headlines are usually related to their technical, predictive, social, and fundamental indicators. Each year, Frost & Sullivan confers this award upon the company that demonstrates excellence in growth and customer value under the Best Practices category. MUMBAI, India, Dec. 14, 2020 /PRNewswire/ -- Guardant Health Asia, Middle East and Africa (AMEA) has won Frost & Sullivan's 2020 Market Leadership Award for Liquid Biopsy in Precision Oncology in AMEA. Guardant Health AMEA is breaking boundaries in advanced cancer diagnostics beyond invasive tissue biopsies, which are considered globally as the standard of care. The offering is expected to close on June 4. Cloudy with periods of snow during the afternoon. Company management will be webcasting a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Guardant is selling 3,750,000 of the shares and SoftBank Investment Advisers is selling the other 7,750,000 shares. Since its launch in 2014, Guardant360 has been ordered by more than 7,000 oncologists and over 60 biopharmaceutical companies. Find real-time GH - Guardant Health Inc stock quotes, company profile, news and forecasts from CNN Business. A simple blood draw helps cancer patients get the right drug. Tarini Singh P: +91-20 6718 9725 E: Tarini.Singh@frost.com. Guardant Health's stock was trading at $62.95 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. … Frost & Sullivan presents the Market Leadership Award to the organization that demonstrates excellence in terms of growth strategy and implementation in its field. Winds NE at 5 to 10 mph. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Now FDA Approved. More About Guardant Health Inc. Guardant Health Inc is a precision oncology company. Guardant Health on Monday announced that the FDA gave emergency use authorization for its coronavirus test.GH stock rose near a buy point on the news before slipping. GH News Today (Guardant Health) | MarketBeat. View the latest Guardant Health Inc. (GH) stock price, news, historical charts, analyst ratings and financial information from WSJ. X. Guardant Health … The company's patient-centric approach proactively addressed challenges associated with the COVID-19 pandemic, such as hospitals facing difficulties in scheduling tissue biopsies. When autocomplete results are available use up and down arrows to review and enter to select. Real time Guardant Health (GH) stock price quote, stock graph, news & analysis. In pursuit of its goal to manage cancer across all stages of the disease, Guardant Health has launched multiple liquid biopsy-based tests, Guardant360 and GuardantOMNI, for advanced stage cancer patients, which fuel its LUNAR development programs for recurrence and early detection. You have permission to edit this article. Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. )+)$)/i, failureMessage: "A valid email address is required"});field1.add(Validate.Format, {pattern: /\.\.|\. Touch device users, explore by touch or with swipe gestures. I would like to take this opportunity to acknowledge all the oncologists who have been ordering our test, our channel partners for their steadfast support and most importantly, the patients who have made Guardant360 their liquid biopsy of choice," said Simranjit Singh, Chief Executive Officer of Guardant Health AMEA. )+[a-z]{2,63}/i);}, failureMessage: "Value must not contain any URL's"});field5.add(Validate.Presence, {failureMessage:"This field is required"});field5.add(Validate.Length, {tooShortMessage:"Invalid length for field value", tooLongMessage: "Invalid length for field value", minimum: 4, maximum: 4});function handleFormSubmit(ele) { var submitButton = ele.querySelector('input[type=submit]'); var spinner = document.createElement('span'); spinner.setAttribute('class', 'loader'); submitButton.setAttribute('disabled', true); submitButton.style.cursor = 'wait'; submitButton.parentNode.appendChild(spinner); return true; }function resetSubmitButton(e){ var submitButtons = e.target.form.getElementsByClassName('submit-button'); for(var i=0;i